<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eur J Clin Invest 2012; 42 (6): 579-588 ABSTRACT: <z:chebi fb="105" ids="17234">Glucose</z:chebi>-based methods are currently gold standards for identifying individuals at risk of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Obviously, these methods only consider one of many pathologies of impaired <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism and they <z:hpo ids='HP_0000001'>all</z:hpo> suffer from a poor specificity as type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> risk assessment tools </plain></SENT>
<SENT sid="2" pm="."><plain>Recently, however, panels of multiple biomarkers reflecting several <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">pre-diabetic</z:e> pathologies have been developed </plain></SENT>
<SENT sid="3" pm="."><plain>Their specificity and potentials for future risk stratification are discussed </plain></SENT>
<SENT sid="4" pm="."><plain>As a multifactorial disorder type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> calls for a multifactorial treatment approach targeting multiple but modifiable vascular risk factors </plain></SENT>
<SENT sid="5" pm="."><plain>The same holds for <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">pre-diabetic</z:e> states and prevention hereof </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and pre-<z:mp ids='MP_0002055'>diabetes</z:mp> show major <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> between affected individuals in pathology, risk of organ damages, progression rate and responsiveness to treatment or prevention </plain></SENT>
<SENT sid="7" pm="."><plain>Despite the <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> and uniqueness of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and pre-<z:mp ids='MP_0002055'>diabetes</z:mp> most affected individuals are currently offered interventions as if they <z:hpo ids='HP_0000001'>all</z:hpo> have the same disease or risk of disease and will respond similarly </plain></SENT>
<SENT sid="8" pm="."><plain>The complex origin and course of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> combined with uniformity and non-specificity of current interventions may explain the high rate of treatment failures and the relative poor prognosis of many <z:mp ids='MP_0002055'>diabetes</z:mp> patients </plain></SENT>
<SENT sid="9" pm="."><plain>Given this situation, the present review also explores the perspectives of selected examples within applied genomics and metagenomics for improving patient care by facilitating interventions tailored to specific subpopulations </plain></SENT>
</text></document>